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HIV-1 Nef Promotes Endocytosis of Cell Surface MHC Class
II Molecules via a Constitutive Pathway1
Ashutosh Chaudhry,2* Divya Anna Verghese,2* Suman Ranjan Das,† Shahid Jameel,†
Anna George,* Vineeta Bal,* Satyajit Mayor,‡ and Satyajit Rath3*
HIV-1 Nef has been reported to disrupt MHC class II (MHCII)-mediated Ag presentation by a dual strategy that comprises a
reduction in cell surface levels of peptide-loaded mature MHCII molecules and a up-regulation of immature MHCII molecules.
We show that Nef achieves relocation of MHCII away from the cell surface in monocytic cells by both delaying its transport to
the cell surface and by accelerating endocytic removal of cell surface MHCII to a lysosomal compartment. Nef-induced MHCII
endocytosis is cholesterol-sensitive but clathrin- and dynamin-independent. Internalized MHCII molecules traverse the early
endosomal system and colocalize with pinocytic cargo before reaching lysosomes. Nef-triggered MHCII endocytosis requires Rab5
activity and lyst function, whereas lysosomal trafficking of internalized MHCII molecules requires Rab7 activity. We further show
that a similar pathway can remove peptide-MHCII complexes from the surface of monocytic cells not expressing Nef. Our data
suggest that Nef uses mechanisms involved in normal MHCII recycling and turnover to mediate the delivery of cell surface MHCII
to a lysosomal destination. Thus, Nef-mediated endocytosis of MHCII provides a novel perspective on the regulation of normal
MHCII trafficking. The Journal of Immunology, 2009, 183: 2415–2424.
T he nonstructural Nef protein of HIV-1 is a critical contrib-utor to viral pathogenicity in a variety of ways (1–4). Nef isa conglomerate of protein-protein interaction modules, in-
tersecting multiple cellular trafficking, and signaling pathways (5, 6).
Nef affects the expression of a variety of molecules on the APC sur-
face that are critical in the generation of immune responses. Notably
Nef mediates the down-regulation of cell surface levels of both classes
of MHC molecules, as well as cell surface levels of the immune co-
stimulatory molecules CD80 and CD86 (7–9).
Viruses that fuse at the plasma membrane and release most of
their proteins directly into the cytosol, as well as viruses that es-
tablish persistent latent infections and constitutively express low
levels of cytosolic Ags, have been found to be effectively detected
by the presentation of cytosolic viral epitopes on MHC class II
(MHCII)4 (10). Viruses use multiple strategies to circumvent
MHCII-dependent immunity, a common one being alteration in the
cellular trafficking of MHCII (11). MHCII molecules extensively
negotiate the endolysosomal system. Nascent MHCII molecules in
complex with the invariant chain (Ii) exit the endoplasmic reticu-
lum and move through the Golgi apparatus before intersecting the
endocytic system in specialized MHCII peptide-loading compart-
ments variously termed MIIC (MHCII-enriched compartment) or
CIIV (class II vesicles) (12, 13). These compartments are thought
to be a collection of late endocytic or lysosomal compartments
containing the necessary components for Ii degradation and effi-
cient peptide loading on MHCII before its egress to the cell surface
(13, 14). Constitutive endocytosis and recycling of cell surface
MHCII have also been well documented (15) and are considered a
pathway for the presentation of some Ags (16), although the mo-
lecular regulators of such trafficking are not yet well understood.
The extensive dependence of MHCII on the endocytic system for
its function offers a potential target for viral subversion.
Nef has been reported to inhibit MHCII-dependent Ag presen-
tation by the reduction of cell surface levels of mature MHCII and
the up-regulation of immature MHCII, which are functionally in-
competent because of persistent association with the Ii (9). In the
presence of Nef, mature MHCII molecules are reduced at the cell
surface and are found at high levels in intracellular lysosomal com-
partments. The delivery of immature MHCII to the endolysosomal
compartment is also impaired, resulting in reduced Ii degradation
(17). Mutational analysis suggests that these mechanisms are well
conserved among nef alleles (18).
Endocytic mechanisms involve a variety of internalization path-
ways with variable dependence on factors such as coat proteins
like clathrin and caveolin, levels of membrane cholesterol, and
scissoring agents such as dynamin (Dyn) and small GTPases of the
Rho family (19, 20). This potentially provides Nef with an assort-
ment of molecular adaptors that can be subverted. Nef is known to
affect many of these endocytic programs to modulate the expres-
sion of several cell surface molecules (4).
On this background, we have examined the process by which
Nef mediates the redistribution of MHCII in human monocytic
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cells. We find that Nef triggers MHCII internalization in a cho-
lesterol-dependent but clathrin- and Dyn-independent manner that
closely mimics the constitutive endocytosis of peptide-MHCII
molecules. These findings indicate that Nef exploits a constitutive
endocytic program to subvert surface MHCII expression in HIV-
infected cells.
Materials and Methods
Plasmids and reagents
The F2-nef gene from an Indian HIV-1 subtype C primary isolate cloned
into pIRES2-EGFP or pEGFP-N3 has been described earlier (7). The
K44A dominant negative (DN)-Dyn construct was obtained from Dr. M.
McNiven (Mayo Clinic, Rochester, MN), the DN Eps15 construct from Dr.
A. Dautry-Varsat (Institut Pasteur, Paris, France), the Rab11 constructs
from Dr. N. Bunnett (University of California, San Francisco, CA), and the
Rab5- and Rab7-related constructs from Dr. M. Zerial (Max Planck Insti-
tute of Molecular Cell Biology and Genetics, Dresden, Germany) for use as
described earlier (21).
The following reagents were used: fluorophore-labeled dextran (tetra-
methylrhodamine-dextran) and transferrin (Tf) (Molecular Probes), mAbs
against Rab5, Rab11, EEA1, LAMP1 (Transduction Laboratories), and
Rab7 (Santa Cruz Biotechnology), anti-human MHCII (L243) either puri-
fied from culture supernatants or used as a biotin conjugate (Serotec), and
purified anti-MHCII mAb labeled with either Cy5 (Amersham), or with
Alexa Fluor dyes (Molecular Probes). The mAbs Y-Ae (anti-Ea52–68-H-
2Ab) and Y3P (anti-H-2Ab) have been described previously (22). Labeled
secondary detection reagents used included goat anti-mouse IgG (Fc)-PE,
donkey anti-rat IgG (Fc)-PE (Jackson ImmunoResearch Laboratories),
streptavidin-PE, streptavidin-CyChrome, and streptavidin-PE-Texas Red
(BD PharMingen).
Cells and transfection
BMC-2 cells were maintained in Click’s medium with FCS, 2-ME, L-
glutamine, and antibiotics. U937 cells were maintained in RPMI 1640 me-
dium with FCS and antibiotics. Cells were kept in 0.5 g/ml LPS overnight
before use to enhance MHC levels. Primary murine monocytes were grown
from mouse bone marrow by culturing nonadherent mouse bone marrow
cells with M-CSF (30% L929 fibroblast-conditioned medium as M-CSF
source) for 7 days, with periodic growth factor replenishment. Primary
human monocytes were grown from PBMC by culturing them with
rM-CSF (100 U/ml; Sigma-Aldrich) for 3 days, and live cells were used
for infection in the continuing presence of the growth factor. Transfec-
tions of cell lines and mouse primary cells were done using FuGENE 6
(Roche) or Effectene (Qiagen), according to the manufacturers’ proto-
cols. Primary human monocytes were transfected by nucleoporation
according to the manufacturer’s protocol (Amaxa). Briefly, 1  106
cells were resuspended in Nucleofector solution followed by the addi-
tion of 4 – 6 g of plasmid DNA and cells were nucleoporated following
manufacturer’s instructions (Amaxa).
Antigens
A recombinant fusion protein (GST-Ea52–68-Myc) consisting of GST, aa
residues 52–68 of the mouse H-2Ea sequence (Ea52–68), and the oligopep-
tide sequence of the c-Myc protein was made in Escherichia coli from the
plasmid pGEX-2T as described previously (22).
Immunofluorescence microscopy and image processing
Cells were fixed with 4% paraformaldehyde for 20 min at 37°C and per-
meabilized using 0.3% Tween 20 or 0.03% saponin in PBS for 20 min at
ambient temperature. They were then blocked with 2 mg/ml BSA in PBS
before incubation with Abs in the same medium. Rabbit and mouse pri-
mary Abs were detected using fluorophore-labeled, Fc-specific anti-rabbit
IgG or anti-mouse IgG.
Confocal and wide field microscopy
Confocal imaging was conducted on a Zeiss LSM510 confocal microscope
(Zeiss) equipped with factory set dichroics and an argon-krypton laser
using the Zeiss software with a step size of 0.1 m and a digital zoom of
3.5 corresponding to a pixel size of 0.10 m was used. Pinhole size was
kept constant at 272 U (optical section, 2 m; airy units, 3), and 12 bit
images were collected at 63 original magnification and a 1.45 numerical
aperture (NA) objective.
Optimized dichroics, excitation, and emission filters were used as de-
scribed (23). Fluorophores were imaged for multiwavelength analysis us-
ing appropriate filter sets. For four-color imaging, either factory-set dich-
roics (Zeiss) or spectral separation by the 32-channel Meta detector (Zeiss)
with dye-specific laser line excitation was used. The absence of cross-
excitation was confirmed in both approaches (data not shown).
High-resolution, wide-field images were collected using Nikon TE 300
inverted microscope equipped with 60 original magnification/1.4 NA
objective and 20 original magnification/0.75 nuclear NA, a mercury arc
illuminator (Nikon), and a cooled charge-coupled device camera (Princeton
Instruments) controlled by Metamorph software (Molecular Devices).
Quantitative colocalization analysis
Colocalization between internalized vesicles and endocytic markers was
quantified using two types of software, MultiSpots and MultiColloc (21,
24), variations of the custom-developed software, Spots and Coloc, respec-
tively, as described previously (21, 25–28). The criteria outlined below
were applied to images obtained from U937 cells labeled with Abs against
Rab5, EEA1, Rab7, Rab11, and LAMP1 or pulsed with the endocytic trac-
ers Tf and dextran for 10 min at 37°C. High-resolution images of cells
labeled with endocytic tracers were obtained using a 60 original magni-
fication, 1.4 NA objective on a wide-field microscope at a pixel resolution
of 0.15um/pixel. The images were corrected for background fluorescence
using the “produce background correction” image procedure in Metamorph
image analysis software with the following parameters suitable for pro-
ducing a local background image while at the same time preserving the
intensity of the endosomes (box size, 30  30 pixels; subsample ratio, 10;
percentile, 0.2).
The background corrected images were then processed through Multi-
Spots to identify endosomes using parameters defined by pixels above a
threshold (set by inspection for each image) and area (minimum, 3 pixel;
maximum, no upper limit). A trimming procedure was applied to isolate
and segregate individual endosomes based on the inclusion of pixels with
intensities 0.3 of maximal intensity within a unit of connected pixels
having an intensity greater than that of the set threshold. This was achieved
by an iterative procedure using a step size (0.01) for each iteration with
limits for the number of iterations of the trimming procedure. The resultant
image contains a set of identified “spots or endosomes” quantified in terms
of net intensity per spot and total pixel area per spot.
The two “spotted” images of different fluorophore-labeled markers were
matched up against each other to identify the endosomes wherein the two
molecules were colocalized. Endosomes in a tracer image (e.g., MHCII-
associated endosomes) were compared with endosomes in a reference im-
age (e.g., Rab11-containing endosomes) using MultiColoc, and endosomes
with 50% area overlap were considered to be colocalized. The resultant
image displayed all of the spots that were colocalized using a particular
“tracer-reference” image pair.
Cell outlines were drawn based on the phase contrast image of the cell,
and the net intensity of each fluorophore per cell was calculated in the
spotted as well as the colocalized images using procedures in Metamorph.
The percentage of colocalization was then calculated from the ratio of the
net intensity within a cell in the MHCII with the appropriate Rab5/EEA1/
Rab11/etc-endocytic marker MultiColoc image to the net spot intensity of
the same cell in the MHCII spots image. The maximum extent of colocal-
ization obtained by this method is 90% for the colocalization of cointer-
nalized Alexa Fluor 568-Tf and Alexa Fluor 647-Tf in the same cell. The
percentage of colocalization is represented as a mean and SEM obtained
from three independent experiments with a minimum of 50 cells per ex-
periment. All images were processed for output purposes using Adobe
Photoshop software. Digital color assignments were made for each fluoro-
phore so as to provide maximum visual contrast.
Cell labeling and other treatments
U937 cells were transfected with various plasmids and surface labeled 12 h
later with either biotinylated or primary-labeled anti-MHCII Ab on ice for
30 min. Cells were then warmed to 37°C and chased for varying lengths
of time.
To visualize the endosomal distribution of the fluorescent tracers, the
cell surface label (fluorophore-labeled Tf or anti-MHCII) was removed by
using a combination of low pH and high pH buffers (ascorbate buffer (pH
4.5),160 mM sodium ascorbate, 40 mM ascorbic acid, 1 mM MgCl2, and
1 mM CaCl2).
Flow cytometry
Cells were stained with primary and secondary reagents on ice for 30 min,
as appropriate. For intracellular staining, cells were permeabilized with
0.03% saponin. Stained cells were analyzed on a BD-LSR flow cytometer
(BD Biosciences) and data were analyzed using FlowJo software (Tree
Star). All data shown are representative of 3–5 independent experiments.
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Viruses and infection
HIV-1 viral stocks were generated by electroporation of HeLa cells with
the infectious molecular clones pNL4-3 and pNL4-3 FS Nef (gifts from H.
Gottlinger, University of Massachusetts Medical School, Worcester, MA)
or pNL4-3 ADA and pNL4-3 ADANef (gifts from M. Stevenson, Uni-
versity of Massachusetts Medical School, Worcester, MA). Virus stocks
were harvested 72 h later and filter sterilized. U937 cells or primary human
monocytes were serum starved for 1 h before infection. For each infection,
1  106 cells were infected with 100,000–200,000 cpm of reverse-tran-
scriptase counts of virus. After 4 h of adsorption, cells were washed and
incubated for 48 h before being stained for surface MHCII and intracellular
p24 Gag protein.
Animals
C57BL/6 and bg/bg mice were obtained from The Jackson Laboratory and
bred in the small animal facility of the National Institute of Immunology
(New Delhi, India). All animal experiments were done under the approval
of the Institutional Animal Ethics Committee.
Results
HIV-1 Nef reduces cell surface MHCII levels in myeloid cells
A wild-type (WT) nef gene (F2-nef) cloned from an Indian clinical
isolate (7) was transfected into the human monocytic U937 cell
line. Cell surface MHCII levels were reduced 5- to 10-fold at 48 h
post-transfection (Fig. 1A). This was accompanied by a reduction
in the levels of MHC class I (MHCI), CD80, and CD86 as reported
earlier (7), whereas levels of other molecules such as the Tf re-
ceptor did not exhibit any changes (Ref. 7 and data not shown).
The total cellular levels of MHCII, however, as measured by stain-
ing postpermeabilization, were unaltered (Fig. 1A). Furthermore,
Nef expression led to a similar reduction of cell surface MHCII
levels in the murine monocytic cell line BMC-2, although there
was no reduction in the total cellular levels of MHCII postperme-
abilization (Fig. 1A). Similar effects were found on primary mouse
bone marrow-derived dendritic cells and monocytes as well (data
not shown). MHCII levels were also dramatically reduced on U937
monocytic cells infected with WT HIV-1, in contrast to cells in-
fected with Nef-deficient HIV-1 (Fig. 1B). The modest residual
reduction in surface MHCII levels in the cells infected with Nef-
deficient HIV-1 could be the effect of the Vpu protein of HIV-1,
which has previously been shown to cause such a modest reduction
in cell surface MHCII levels in monocytic cells (29).
We next tested whether the reduction of cell surface MHCII
levels observed in Nef-expressing U937 cells or in mouse mono-
cytic cells was also observed in primary human monocytes. Human
primary monocyte cultures were transfected to express enhanced
GFP (eGFP) alone or Nef and eGFP. Expression of Nef in human
primary monocytes also led to a reduction in cell surface MHCII
levels (Fig. 1C). We also confirmed that the infection of primary
human monocytes with WT HIV-1 (Ada strain) led to substantial
loss of cell surface MHCII levels, whereas infection with Nef-
deleted HIV-1 (Ada) did so only modestly (Fig. 1D, right panel).
It is noteworthy that, under the conditions used, the two viruses did
not show notable differences in their ability to infect primary hu-
man monocytes (Fig. 1D, left panel). Thus, a reduction in cell
surface MHCII levels by Nef is relevant for the human monocytic
lineage.
To further characterize Nef-mediated down-modulation of MH-
CII in monocytic cells, we tested some Nef mutants we have pre-
viously reported on for their effects on MHCI down-modulation in
myeloid cells, using either the human cell line U937 and/or the
mouse cell line BMC-2. All findings were consistent between the
two cell lines. As expected, the GG to AA mutation of Nef at
residues 2 and 3 (G2A), known to be deficient in myristoylation,
was unable to down-regulate MHCI or MHCII (Table I). Deletion
mutants of Nef truncated from the C terminus to residue 130 con-
tinued to show efficient down-modulation of MHCI and MHCII,
and while further deletion to residue 105 led to a loss of MHCI
down-modulation, this mutant continued to down-modulate
MHCII. However, a further deletion to residue 78 led to a loss of
FIGURE 1. HIV-1 Nef reduces cell surface but not total MHCII levels on human and mouse myeloid cells. A, U937 or BMC-2 cells were transfected to express
either eGFP alone (black lines) or Nef and eGFP (red lines) and stained 24 h later for MHCII either before (surface) or after (total) permeabilization. Histograms
show MHCII levels on eGFP-gated cells. B, U937 cells were either mock infected (black line) or infected with WT HIV-1 (NL4-3; blue line) or with nef-deleted
NL4-3 virus (red line) and stained for cell surface MHCII and intracellular HIV-1 p24 protein 2 days later. Histograms show surface MHCII levels on p24-gated
cells. C, Primary human monocytes were transfected to express either eGFP alone (black lines) or Nef and eGFP (blue lines) and stained 24 h later for cell surface
MHCII. Histograms show MHCII levels on eGFP-gated cells. D, Primary human monocytes were either mock infected (black line) or infected with WT HIV-1
(NL4-3 Ada; red line) or nef-deleted NL4-3 Ada virus (blue line) and stained for cell surface MHCII and intracellular HIV-1 p24 protein 2 days later. Histograms
in the left panel show p24 levels in infected cells and the p24 gate used. Histograms in the right panel show surface MHCII levels on p24-gated cells. E, U937
cells transfected to express either eGFP alone (black lines) or Nef and eGFP (red lines) were stained 12 h after transfection with anti-MHCII-biotin or anti-
CD80-biotin, and held at either 4°C or 37°C as indicated. Cells were then stained with the same anti-MHCII or anti-CD80 mAbs conjugated to PE to detect newly
expressed molecules. Histograms show levels of new MHCII or CD80 molecules delivered to the cell surface as detected by PE-labeled mAbs in eGFP-gated cells.
Gray curves in all panels represent isotype controls. Data are representative of 3–5 independent experiments.
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down-modulation of both MHCI and MHCII (Table I). A clinical
isolate of Nef mutated in both the WL57 site and the phosphofurin
acidic cluster-sorting protein (PACS)-binding E4 site (D1-Nef) (7)
also showed a loss of MHCI- and MHCII-down-modulation ac-
tivity (Table I).
Nef retards the delivery of MHCII molecules to the plasma
membrane
Previous reports regarding the effects of Nef on cell surface
MHCII levels could be interpreted to imply that Nef reduces the
rate of MHCII delivery to the cell surface as well as acceler-
ating the removal of cell surface MHCII molecules. We tested
both of these possibilities. To test the effect of Nef on the de-
livery of intracellular MHCII to the cell surface, Nef-expressing
U937 cells were stained 12 h after transfection with biotinylated
anti-MHCII or anti-CD80 mAbs. They were then either held at
4°C or cultured at 37°C for 2 h. The cells were then stained with
Cy3-streptavidin to detect the prelabeled molecules, as well as
with the same anti-MHCII or anti-CD80 mAbs conjugated to
PE to detect newly expressed molecules. Because the cell sur-
face MHCII and CD80 were saturated with the first round of
mAb binding, no staining was seen with the second round PE-
labeled mAbs when the cells had been held at 4°C, showing that
no new MHCII or CD80 molecules had arrived at the surface
(Fig. 1E). However, if the cells were held at 37°C for 2 h,
unlabeled CD80 appeared on the surface and the extent of ex-
pression of unlabeled CD80 was not different between eGFP-
expressing or Nef-eGFP-expressing cells, indicating that Nef
did not affect the rate of exocytosis of CD80 molecules to the
cell membrane. In contrast, whereas newly delivered MHCII
molecules could indeed be detected in cells held at 37°C, their
levels were lower in Nef-expressing cells (Fig. 1E), indicating
that Nef retards the delivery of intracellular MHCII molecules
to the cell surface.
Nef relocates cell surface MHCII to intracellular lysosomal
compartments
Nef-mediated internalization of cell surface MHCII was next
tracked by the disappearance of MHCII from the cell surface
over time in eGFP- or Nef-expressing U937 cells, by labeling
surface MHCII with biotinylated mAb and chasing for various
times before flow cytometric estimation of surface label loss
with fluorophore-labeled streptavidin. To confirm that the label
lost from the surface was retained intracellularly, cells were
also permeabilized and stained at each chase time point. The
data show that in the absence of Nef, MHCII resides stably at
the cell surface over an 8-h period, whereas in the presence of
Nef MHCII was progressively lost from the surface but re-
mained detectable intracellularly (Fig. 2A). We also tracked the
internalization of cell surface MHCII molecules by label-
ing Nef-transfected U937 cells with fluorochrome-tagged
FIGURE 2. Nef traffics cell surface MHCII to lysosomal compartments.
A, U937 cells transfected to express either GFP alone or Nef and eGFP as
indicated were surface labeled with anti-MHCII-biotin 12 h after transfec-
tion and then cultured for various times as indicated and subjected to the
detection of either surface (open symbols) or total (closed symbols) label
postpermeabilization. Mean fluorescence intensities were calculated for
eGFP-gated cells and the data normalized to the starting intensities as a
percentage of the residue of surface-labeled MHCII. The graphs show
mean  SD values of detected fluorescence label calculated from three
independent experiments. B, U937 cells transfected to express eGFP (left
column) or Nef-eGFP (right column) were surface-labeled 12 h later with
anti-MHCII-biotin, and were either stained with labeled streptavidin-Alexa
Fluor 568 immediately (0 h; top row) or cultured for 16 h before staining
(16 h; bottom row), followed by confocal microscopic imaging. Scale bar,
10 m. C, U937 cells transfected to express eGFP (left) or Nef-eGFP
(right) were fixed 24 h after transfection and stained for MHCII (red; Alexa
Fluor 568) and LAMP-1 (blue; Alexa Fluor 647), followed by confocal
microscopy. Scale bar, 10 m. D, U937 cells expressing Nef-eGFP were
labeled for MHCII at the cell surface and cultured for various times as
indicated. At each time point shown the surface label was stripped and cells
were permeabilized and stained for the vesicular marker indicated. For
detection of Arf6, U937 cells were cotransfected with plasmids expressing
Nef-HA and Arf6-eGFP, and staining include hemagglutinin epitope de-
tection. For tracking colocalization with dextran (Dex) or Tf, cells were
given a 10-min pulse with fluorophores, Alexa Fluor 568-Tf or tetrameth-
ylrhodamine-Dex 3 h after surface labeling for MHCII. Cells were imaged by
either high-resolution, wide-field fluorescence microscopy or confocal micros-
copy. Images of Nef-expressing cells were quantified for the fraction of inter-
nalized MHCII colocalizing with the various markers shown. Data are plotted
as the extent of colocalization over time (mean  SE; n  100 cells).
Table I. Effects of Nef mutations on Nef-mediated down-modulation of
cell surface MHCII in monocytic cell lines
Mutants
U937 Human Cellsa BMC-2 Mouse Cellsa
MHCIb MHCII MHCIb MHCII
F2-nef (WT)    
F2-nef-G2A    
F2-nef-78    
F2-nef-105  ()  ()
F2-nef-125 () () () ()
D1-nef  ()  ()
a , Persistence of down-modulation ability; , loss of down-modulation ability;
(), weak persistence of down-modulation.
b MHCI-related data from Ref. 7.
2418 Nef SUBVERTS CONSTITUTIVE MHCII ENDOCYTOSIS
 o
n
 N
ovem
ber 30, 2010
w
w
w
.jimmunol.org
D
ow
nloaded from
 
anti-MHCII Ab, followed by confocal microscopic examination
over time. By 16 h after surface labeling, MHCII molecules had
disappeared from the surface of Nef-expressing, but not from
control eGFP-expressing U937 cells, and were relocated in in-
tracellular compartments (Fig. 2B).
To identify the intracellular compartment where MHCII was
located in Nef-expressing cells, we examined Nef-eGFP-express-
ing U937 cells for colocalization of MHCII with markers of in-
tracellular compartments by confocal microscopy. Nef-eGFP was
colocalized with endogenous MHCII in intracellular organelles
marked by the lysosomal marker LAMP-1 (Fig. 2C). Although
almost all cell surface MHCII was relocated under the influence of
Nef into some LAMP-1-marked compartments, LAMP-1-marked
compartments not containing MHCII could also be detected (Fig.
2C), indicating that Nef induced MHCII relocation to specific ves-
icles within LAMP-1-marked regions.
Nef redistributes surface MHCII to the lysosomal compartment
via endosomal vesicles
We next examined the colocalization of internalized MHCII in
Nef-expressing cells with a range of vesicular and endosomal
markers at intermediate stages of internalization to track the path-
way of internalization (Fig. 2D). Internalized MHCII molecules in
Nef-expressing cells initially colocalized in vesicles bearing Rab5.
If the cells were pulsed with either Tf or a fluid-phase marker,
tetramethylrhodamine-dextran at appropriate times, initial colocal-
ization was seen with both markers; but whereas Tf was rapidly
sorted away from the MHCII, dextran showed stable colocaliza-
tion. As MHCII-carrying endosomes lost Rab5, they moved into
Rab7-bearing compartments from where they began to accumulate
stably in LAMP-1-bearing vesicles. No colocalization was seen
with either Arf6 or Rab11. These results suggest that, under the
influence of Nef, MHCII traffics from early endosomal compart-
ments to lysosomes along with fluid-phase cargo via late endoso-
mal compartments, following the classical pathway of postendo-
cytotic progression.
Molecular mediators of Nef-induced MHCII endocytosis
We next attempted to identify the molecular intermediates critical
for Nef-mediated endocytosis of cell surface MHCII. Because Nef
induces both an exocytic blockade and an enhanced endocytosis of
MHCII, we distinguished between these two processes in many of
the following experiments by using the methodology described
above, namely labeling surface MHCII with biotinylated mAb and
chasing for various times before flow cytometric estimation of sur-
face label loss with fluorophore-labeled streptavidin. However, de-
tection of cellular levels of MHCII without prior labeling also gave
similar results in all instances.
Because MHCII molecules that are being internalized under the
influence of Nef first enter compartments marked by the small
GTPase Rab5, we examined whether Rab5 was involved in the
process of removal. For this, U937 cells were cotransfected with
Nef and either WT Rab5 or a DN mutant (S34N) (30) version of
Rab5. Cells were stained 36 h later for cell surface MHCII or
MHCI. In cells coexpressing Nef with DN Rab5, MHCII internal-
ization was notably reduced whereas MHCI relocation was not
blocked (Fig. 3A). Similar data were obtained when cell surface
MHCII molecules were prelabeled and chased. The removal of pre-
labeled MHCII from the surface of Nef-expressing U937 cells was
retarded by DN Rab5, and was accelerated by a constitutively active
(CA) (30) mutant (Q79L) of Rab5 (Fig. 3B). These data thus impli-
cated Rab5 in the Nef-mediated removal of cell surface MHCII
and indicated a difference between the mechanisms of Nef-induced
trafficking of cell surface MHCI and MHCII.
As shown above, Nef-mediated endocytosis of surface MHCII
was followed by their delivery from early Rab5-bearing endo-
somes to late Rab7-bearing endosomes. A protein encoded by the
lyst gene is known to modulate this trafficking. The beige mouse
strain (Bg) harbors a mutation in the lyst gene and its cells show
reduced sorting to late endosomal compartments (31). Because Nef
had similar effects on the removal of surface MHCI and MHCII in
FIGURE 3. Nef-mediated removal of cell surface MHCII requires Rab5
and Lyst. A, U937 cells were either singly transfected or cotransfected for
expression of hemagglutinin epitope (HAp) alone or F2-Nef-HAp and WT
Rab5 or DN Rab5 in combinations as indicated. Cells were stained for cell
surface MHCI or MHCII 24 h later and analyzed by flow cytometry. Sin-
gle-color histograms show surface MHCI or MHCII levels on HAp-gated
cells. Isotype controls are shown as gray-shaded curves. B, U937 cells were
either singly transfected or cotransfected for expression of HAp alone or
F2-Nef-HAp and WT Rab5, CA Rab5, or DN Rab5 in combinations as
indicated. Cells were stained with anti-MHCII-biotin 12 h later and cul-
tured for various times as shown before detection of the residual cell sur-
face label. Mean fluorescence intensities were calculated for HAp-gated
cells and the data were normalized to the starting intensities as a percentage
of the residue of surface-labeled MHCII as shown. C, BMDMs derived
from WT C57BL/6 or bg/bg (Bg) mice were transfected to express either
eGFP alone (yellow curves) or Nef and GFP (black lines) and stained for
cell surface MHCI or MHCII 24 h later for analysis by flow cytometry.
Single-color histograms show surface MHCI or MHCII levels on eGFP-
gated cells. Isotype controls are shown as gray-shaded curves.
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mouse myeloid cells (Ref. 7 and data above), we used bone mar-
row-derived monocytes (BMDMs) grown from either WT or Bg
mice and transfected to achieve Nef expression. Nef-expressing Bg
BMDMs showed reduced loss of surface MHCII although MHCI
relocation was unaffected (Fig. 3C), again indicating that Nef-me-
diated removal of MHCII was dependent on the endocytotic traf-
ficking pathway from early to late endosomes.
We (24) and others (32) have previously reported that MHCI
removal from the cell surface in Nef-expressing cells is dependent
on cholesterol and phosphatidylinositol kinase (PIK) activity. We
therefore tested whether MHCII removal in Nef-expressing cells
was similarly controlled. Cellular cholesterol was depleted in
U937 cells using the cholesterol-chelating agent methyl--cyclo-
dextrin (MBCD). MHCII removal from the cell surface was sen-
sitive to MBCD (Fig. 4A) like MHCI removal (24). Low concen-
trations of wortmannin (Wm), a PIK inhibitor reported to be
specific for PI3K (33), did not affect Nef-mediated removal of
MHCII whereas a higher concentration retarded it (Fig. 4B), sim-
ilar to the finding for MHCI removal (24).
Although Nef-mediated CD4 internalization is Dyn dependent,
that of MHCI, CD80, or CD86 is not (34). We therefore tested the
effect of the DN K44N mutant of Dyn-2 (DN Dyn) (35) or that of
a short interfering RNA for Dyn-2 (sh-Dyn) (36) on Nef-mediated
MHCII down-modulation in Nef-expressing U937 cells. DN Dyn
had no effect on Nef-induced loss of cell surface MHCII (Fig. 4C)
or MHCI, CD80, or CD86 as reported earlier (24), although Dyn-
dependent Tf endocytosis was blocked as expected (Fig. 4C). Sim-
ilarly, sh-Dyn did not have any effect on the Nef-induced removal
of cell surface MHCII (Fig. 4D). DN versions of other GTPases
known to be involved in many endocytotic pathways, such as Rho
or Cdc42, did not have any effects on the removal of either MHCII
or MHCI in Nef-expressing cells (data not shown). Furthermore,
the blockade of molecular activities known to be crucial for the
removal of the costimulatory molecules CD80 and CD86 from the
surface of Nef-expressing myeloid cells, such as Rac, WASP,
TIAM, Src, protein kinase C, or actin (24), had no effect on the
reduction of surface MHCII levels in Nef-expressing cells (data
not shown).
FIGURE 4. Nef-mediated removal of cell surface MHCII is dependent on cholesterol and PIK but is independent of Dyn, Eps15, or intersectin. A and
B, U937 cells transfected to express either eGFP alone or Nef and GFP were cultured in the presence or absence of various concentrations of MBCD (A)
or Wm (B) as indicated. Cells were stained with anti-MHCII 12 h later and cultured for various times as shown before detection of the residual cell
surface label. Mean fluorescence intensities were calculated for eGFP-gated cells and the data normalized to the starting intensities as a percentage of the
residue of surface-labeled MHCII as shown. C, U937 cells were transfected to express either eGFP or Nef and GFP and WT Dyn or DN Dyn as shown.
Cells were stained with anti-MHCII 12 h after transfection and cultured for various times as shown before detection of the residual cell surface label. Mean
fluorescence intensities were calculated for eGFP-gated cells and the data normalized to the starting intensities as a percentage of the residue of surface-
labeled MHCII as shown (left panel). Right panel shows U937 cells transfected to express eGFP alone or with either WT Dyn or DN Dyn as indicated and
given a 10-min pulse with fluorophore-labeled Tf 3 h before staining. Histograms show Tf uptake levels in eGFP-gated cells. Gray curves indicate isotype
controls. D, U937 cells were transfected to express either eGFP alone (yellow curves) or Nef-positive GFP alone (black line) or with either control plasmid
(blue line) or sh-Dyn (red line). Cells were stained 24 h later for MHCII. Histograms show surface MHCII levels on eGFP-gated cells. Gray curves indicate
isotype controls. E and F, U937 cells were transfected to express either eGFP alone (yellow curves) or Nef and GFP alone (black line) or with DN eps15
(red line; E) or intersectin-A (red line; F). Cells were stained 24 h later for cell surface MHCI or MHCII. Histograms show surface MHCI and MHCII levels
on eGFP-gated cells. Gray curves indicate isotype controls. G, Human primary monocytes were either untransfected (yellow curves) or transfected to
express Nef by itself (black line) or along with either WT Eps15 (left panel; blue line) or DN Eps-15 (left panel; red line) or WT Rab5 (right panel; blue
line) or DN Rab5 (right panel, red line). Cells were stained 24 h later for MHCII. Histograms show surface MHCII levels on cells gated for expression
of transfected gene/s. Gray curves indicate isotype controls.
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To assess the role of clathrin in Nef-induced MHCII internal-
ization, U937 cells were cotransfected with Nef and either a DN
version of the clathrin adaptor protein Eps15 (95/295) (37) or a DN
fragment of another adaptor protein, intersectin (intersectin-A)
(38). DN Eps-15 and intersectin-A blocked the uptake of Tf as
expected (data not shown). In cells coexpressing Nef with DN
Eps15 or intersectin-A, MHCII internalization was unaffected
while MHCI relocation was blocked (Figs. 4, E and F), identifying
another difference between the Nef-induced trafficking pathways
for MHCI and MHCII.
Together, these data indicate that although mechanisms for cell
surface MHCI and MHCII removal in Nef-expressing cells have
some similarities, they differ in their entry into Tf- and fluid phase-
marked compartments and in their dependence on clathrin com-
plexes vs Rab5 and Lyst activity.
We also confirmed that the role for Rab5 and the lack of a role
for Eps15 in Nef-mediated relocation of MHCII was relevant in
primary human monocytes as well. Human primary monocyte cul-
tures were cotransfected to express Nef with either WT Rab5/DN
Rab5 or WT Eps15/DN Eps15 as above and stained to assess sur-
face MHCII levels. DN Rab5 blocked Nef-mediated relocation of
MHCII whereas DN Eps15 did not (Fig. 4G), confirming that the
observations on U937 cells were consistent with those on primary
human monocytes.
Cell surface MHCII was sorted to LAMP-1-bearing compart-
ments via Rab7-bearing vesicles in Nef-expressing cells as shown
above. The endocytosis of MHCII from the surface in Nef-express-
ing cells appears to be controlled by Rab5 and Lyst. We therefore
examined whether Rab7 was crucial in mediating the Nef-medi-
ated lysosomal delivery of MHCII. U937 cells were cotransfected
with Nef and a DN mutant (N125I) version of Rab7. DN Rab7 did
not block removal of cell surface MHCII (Fig. 5A). However, al-
though internalized MHCII was relocated to LAMP-1-bearing
compartments in Nef-expressing cells carrying WT Rab7, this co-
localization was blocked in DN Rab7-expressing cells (Figs. 5, B
and C), demonstrating that Rab7 is critical for lysosomal delivery
of internalized MHCII.
Endocytic intermediates involved in constitutive turnover of
peptide-MHCII complexes
The data above indicated that Nef-mediated endocytotic removal
of cell surface MHCII in both human and mouse myeloid cells was
initiated by cholesterol- and PIK-dependent events requiring both
Rab5 and Lyst. We next examined whether Nef assembled this de
novo pathway for MHCII internalization or whether it subverted
an existing pathway in the constitutive turnover of MHCII mole-
cules. For this purpose, we generated specific peptide-MHCII
(pMHCII) complexes on the surface of the mouse monocytic cell
line BMC-2 and tracked its fate using a mAb specific for this
pMHCII complex. A peptide from the endogenous protein H-2E-
(Ea52–68; Eap) binds with high affinity to the H-2Ab MHCII mol-
ecule, and this pMHCII complex is specifically recognized by the
Y-Ae mAb (39). Therefore, cell surface pMHCII complexes were
generated by pulsing BMC-2 cells with synthetic Eap for 60 min.
Pulsed cells were incubated for varying times before being stained
with either the pMHCII-specific mAb Y-Ae or the H-2Ab-specific
mAb Y-3P for flow cytometry (Fig. 6A) or were labeled at 4°C
with biotinylated Y-Ae or Y-3P and then incubated for varying
times at 37°C followed by flow cytometric detection using
fluorochrome-coupled streptavidin (Fig. 6B). Y-Ae-binding pMHCII
complexes generated on BMC-2 cells were lost rapidly from the
cell surface, whereas the total H-2Ab levels did not show any no-
table change (Figs. 6, A and B). We then examined whether the
molecular intermediates involved in Nef-mediated removal of cell
surface MHCII also regulated the specific loss of Y-Ae-binding
pMHCII complexes from the cell surface.
For this, BMC-2 cells were pulsed with Eap for 1 h at 37°C and
labeled with biotinylated Y-Ae at 4°C as above, followed by in-
cubation for varying times in the presence or absence of MBCD or
Wm before the detection of levels remaining at the cell surface.
The pMHCII complexes were lost more slowly from the surface if
cholesterol was chelated (Fig. 6C). Also, although a low Wm con-
centration did not affect the rate of removal of pMHCII complexes,
a higher concentration, which has been reported to inhibit other
PIKs in addition to PI3K (33), also retarded the loss of surface
pMHCII (Fig. 6D).
To examine the role of Rab5, BMC-2 cells were transfected with
constructs driving the expression of WT Rab5-eGFP, DN Rab5-
eGFP, or CA Rab5-eGFP. Cells were pulsed 12 h posttransfection
with Eap and labeled with Y-Ae as above and incubated for
varying times before the detection of residual surface levels.
The pMHCII complexes were lost more slowly from the surface of
DN Rab5-expressing cells, while they were lost more rapidly in
CA Rab5-expressing cells (Fig. 6E).
We also examined the rate of loss of surface pMHCII complexes
from WT and Bg cells. As described above, BMDMs grown from
either WT or Bg mice were used. Cells were pulsed with Eap and
labeled with Y-Ae as above and the loss of surface label was
tracked. Bg BMDMs showed a slower loss of surface pMHCII
complexes compared with WT cells (Fig. 6F).
In similar assays, we also examined the effect of blocking mo-
lecular activities crucial for Nef-mediated removal of other cell
FIGURE 5. Rab7 is required for lysosomal delivery of MHCII removed
from the surface in Nef-expressing cells. A, U937 cells were either singly
transfected or cotransfected for expression of hemagglutinin epitope (HAp)
alone or F2-Nef-HAp or WT Rab7 or DN Rab7 in combinations as indi-
cated. Cells were stained with anti-MHCII-biotin 12 h later and cultured for
various times as shown before the detection of residual cell surface label.
Mean fluorescence intensities were calculated for HAp-gated cells and the
data normalized to the starting intensities as a percentage of the residue of
surface-labeled MHCII. B, U937 cells transfected to express Nef-GFP with
either WT Rab7 or DN Rab7-eGFP (blue) were fixed 24 h after transfection
and stained for MHCII (green; Alexa Fluor 647) and LAMP-1 (red; Alexa
Fluor 568) followed by confocal microscopy. Insets show gray-scale im-
ages of the same cells for cyan and blue colors as identified by the inset
frames. C, Nef-HAp-expressing cells from the experiment shown in B
above were quantified for the fraction of internalized MHCII colocalizing
with LAMP-1 in the presence of WT Rab7 or DN Rab7 (mean  SE; n 
50 cells).
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surface molecules on the rate of pMHCII removal. Blocking the
activities of WASP, Dyn, or Eps15 had no effect on the rate of loss
of pMHCII complexes from the surface of BMC-2 cells (data not
shown).
Together, these data indicate that short-lived pMHCII com-
plexes on mouse monocytic cells, even in the absence of Nef, are
removed from the cell surface by an endocytotic mechanism de-
pendent on cholesterol, PIK, Rab5, and Lyst. This concordance
between the trafficking pathways of total cell surface MHCII in
Nef-expressing cells and those of specific pMHCII complexes in
non-Nef-expressing cells suggests that Nef may be subverting con-
stitutive pathways of MHCII endocytosis for the removal of cell
surface MHCII molecules.
Discussion
In epithelial cells expressing the CIITA, Nef has been reported to
affect MHCII-mediated Ag presentation by altering the intracellu-
lar trafficking of MHCII molecules to reduce the levels of mature
MHCII and increase immature MHCII on the cell surface (9). Be-
cause Ii-associated immature MHCII is functionally incompetent,
an immune evasion function has been suggested (9). The delivery
of immature MHCII to the lysosomes is also impaired, resulting in
reduced Ii degradation (17). However, in the presence of Nef, MH-
CII is found at high levels in intracellular lysosomal compart-
ments. Our results now extend these findings to professional APCs
of the myeloid lineage and identify some molecular intermediates
used by Nef to induce surface MHCII-down-regulation. We find
that this pathway is similar to that used in constitutive endocytosis
of peptide-MHCII complexes, indicating that Nef subverts a pre-
existing MHCII endocytic program.
Human as well as mouse myeloid cells are sensitive to these
effects of Nef, and these observations are consistent between cell
lines and primary monocytes of both human and mouse origin. The
phenomenon is likely to be of some pathophysiological signifi-
cance, because Nef-dependent loss of cell surface MHCII is seen
on HIV-1 infection, although there are significant differences be-
tween the laboratory strain of HIV-1 and clinical isolates, raising
the possibility of interesting variations in this property in the latter
group. The loss of cell surface MHCII in monocytic cells express-
ing Nef is not accompanied by any loss of total cellular levels of
MHCII, indicating that Nef mediates a cellular redistribution of
MHCII. This characteristic is also seen with regard to MHCI,
FIGURE 6. Peptide-MHCII complexes are removed from the cell surface by a mechanism at least partially dependent on cholesterol, PIK, Rab5, and
Lyst. A, BMC-2 cells were pulsed with Eap for 60 min and cultured for 0 h (black line), 3 h (blue line), 6 h (red line), or 9 h (green line) before staining
with either the pMHCII-specific mAb Y-Ae or the H-2Ab -specific mAb Y-3P for flow cytometry. Gray curves indicate isotype controls. Mean fluorescence
intensities were calculated for HAp-gated cells and the data normalized to the starting intensities as a percentage of the residue of surface label. B, BMC-2
cells were pulsed with Eap for 60 min and stained with either Y-Ae or Y-3P and cultured for 0 h (black line), 3 h (blue line), 6 h (red line), or 9 h (green
line) before flow cytometric detection of residual cell surface label. Gray curves indicate isotype controls. Mean fluorescence intensities were calculated
and the data normalized to the starting intensities as a percentage of the residue of surface label. C and D, BMC-2 cells were pulsed with Eap for 60 min
and stained with either Y-Ae or Y-3P and cultured for various times in the presence or absence of various concentrations of MBCD (C) or Wm (D) as
indicated before detection of the residual cell surface label. Mean fluorescence intensities were calculated and the data normalized to the starting intensities
as a percentage of the residue of surface label. E, BMC-2 cells transfected to express either eGFP alone or with WT Rab5, CA Rab5, or DN Rab5 as
indicated were pulsed with Eap for 60 min and stained with either Y-Ae or Y-3P and cultured for various times as shown before detection of the residual
cell surface label. Mean fluorescence intensities were calculated and the data normalized to the starting intensities as a percentage of the residue of the
surface label. F, BMDMs derived from WT C57BL/6 or bg/bg (Bg) mice were pulsed with Eap for 60 min and stained with either Y-Ae or Y-3P and
cultured for various times as indicated before detection of residual cell surface label. Mean fluorescence intensities were calculated and the data normalized
to the starting intensities as a percentage of the residue of surface label.
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including our observation of a clinical isolate that is inefficient in
the down-modulation of MHCI and MHCII, but not in that of
CD80 and CD86.
The removal of cell surface MHCII could be the result of re-
duced delivery to the cell surface and/or enhanced removal by
endocytosis. Unlike the case for MHCI, CD80, and CD86 (Ref. 7
and data not shown), MHCII delivery to the cell surface is retarded
in Nef-expressing cells. However, Nef induces endocytic removal
of all four of these target molecules. The eventual intracellular
destinations of these molecules in Nef-expressing cells, are how-
ever, quite distinct. Although MHCI, CD80, and CD86 are re-
moved to the Golgi region, MHCII relocates to the lysosomal
compartment.
Similarly, the differences between the vesicular trafficking path-
ways followed by these target molecules in Nef-expressing cells
are different and noteworthy. We observed recently that CD80 and
CD86 are internalized into vesicles that do not show any markers
of endosomal compartments and that they recruit Rab11 after a lag
of some hours, using Rab11 activity for cargo delivery to the
Golgi, although Rab11 activity is not required for the Golgi local-
ization of MHCI (40). In contrast, both MHCI (41) and MHCII
enter early endosomal compartments marked by Rab5 and either
fluid cargo and/or Tf. However, their pathways then diverge.
MHCI molecules go on to the sorting compartment marked by
Arf6 and then to the Golgi apparatus (41), whereas MHCII mol-
ecules move to the late endosomes marked by Rab7 and then to a
LAMP-1-bearing lysosomal compartment using Rab7 activity.
Similarly, we find that the molecular intermediates involved in
the Nef-mediated endocytosis of these four target molecules show
major differences. CD80 and CD86 follow a unique endocytosis
pathway defined by its dependence on protein kinase C, c-Src,
TIAM, Rac, and actin and by being independent of cholesterol,
clathrin, Dyn, and PIK activity (24). In fact, we have not to date
found any molecular intermediates shared by CD80/CD86 on the
one hand and MHCI/MHCII on the other. However, MHCI and
MHCII also show striking differences in the signaling intermedi-
ates used for their Nef-mediated endocytosis. Although both are
cholesterol- and PIK-dependent and Dyn-independent, MHCI ap-
pears to use some form of the clathrin-adaptor complex whereas
MHCII does not. Although both enter Rab5-containing vesicles,
MHCI endocytosis does not depend on Rab5 or Lyst activity,
whereas MHCII endocytosis does.
It is thus possible to argue for a model in which recycling MHCI
enters sorting endosomes for a decision on whether they will be
recycled back to the cell surface or not, which is where Nef may
intervene and reroute them to the Golgi apparatus (41). However,
MHCII molecules may recycle through an early endosomal com-
partment dependent on the homologous fusion of early endosomes
controlled by Rab5 so that the lack of Rab5 activity may lead to
default delivery to late endosomes and then by normal endolyso-
somal Rab7-dependent maturation mechanisms to the lysosomes.
Because Bg cells show defective trafficking to the late endosomal
compartments and increased ability of these lysosomes to fuse with
the plasma membrane (42, 43), the loss of Nef-mediated MHCII
down-regulation in Bg cells can perhaps be explained either by
enhanced recycling back to the cell surface from early endosomes
and/or by fusion of Bg lysosomes with the plasma membrane.
Such organized and branching cascades of signaled traffic sug-
gests that Nef may be using pre-existing pathways normally used
for the control of trafficking and turnover for these molecules. It is
also of interest in this connection to note that, although Nef does
bind to the cytosolic tails of CD80 and CD86 directly, evidence
regarding its recruitment to the cytoplasmic portions of either
MHCI or MHCII is sparse (9, 44), suggesting a possible alteration
of normal turnover pathways rather than a directly induced endo-
cytosis. We examined this possibility by testing whether peptide-
MHCII complexes on the cell were normally internalized and, if
so, whether the signaling intermediates needed for Nef-dependent
removal of cell surface MHCII were also involved in the normal
removal of pMHCII complexes. Our data indicate that pMHCII
complexes are short lived on the cell surface and that their loss is
indeed significantly dependent on cholesterol, PIK, Rab5, and Lyst
activity.
There is thus a considerable degree of overlap between the
molecular intermediates that are involved in the removal of Y-
Ae-reactive pMHCII complexes from the APC surface and
those involved in the Nef-induced internalization of MHCII
molecules. Both endocytic programs are sensitive to cholesterol
depletion, require PIK activity, are dependent on Lyst as well as
Rab5 function, and intracellular trafficking of the internalized
complexes is Rab7 dependent. Thus, Nef appears to subvert a
constitutive endocytic program that removes pMHCII com-
plexes from the cell surface to mediate the removal of all
MHCII molecules from the cell surface. How does Nef mediate
the accelerated removal of MHCII molecules by such a consti-
tutive pathway? In this context, an interesting difference be-
tween Nef-mediated MHCII removal and constitutive removal
of pMHCII complexes is notable. The constitutive program ap-
pears to remove specific pMHCII complexes rapidly from the
cell surface over time without affecting the equilibrium MHCII
levels, whereas Nef extends this short-lived property to all cell
surface MHCII molecules. Nef clearly retards the exocytosis of
newly formed MHCII molecules, including their delivery to the
endolysosomal compartments (17), and we have observed in
preliminary experiments that that inhibition of protein synthesis
in normal APCs leads to a rapid loss of pre-existing cell surface
MHCII molecules (data not shown). It is thus possible to visu-
alize an intriguingly novel model in which the recycling of
MHCII from endosomal compartments is dependent on the
availability of new peptide as well as MHCII in those compart-
ments, and their lack leads to a sorting decision in favor of
lysosomal delivery. Further studies will be needed to establish
the validity and mechanisms of such a process.
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